FDA: GSK's Zofran might increase risk of abnormal heart rhythm

09/15/2011 | Wall Street Journal, The

The FDA is investigating the safety of GlaxoSmithKline's Zofran, or ondansetron, because of concern that the treatment increases the risk of abnormal heart rhythm. Zofran prevents nausea and vomiting in patients undergoing chemotherapy, surgery and radiotherapy. The FDA said it will add recommendations to Zofran's label, including electrocardiogram monitoring in certain patients.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA